human adenovirus type 5 encoding hpv-16 e6/e7 vaccine ibrx-042
Generic: Human Adenovirus Type 5 Encoding HPV-16 E6/E7 Vaccine IBRX-042
human adenovirus type 5 encoding hpv-16 e6/e7 vaccine ibrx-042: 1 clinical trial tracked.
human adenovirus type 5 encoding hpv-16 e6/e7 vaccine ibrx-042 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about human adenovirus type 5 encoding hpv-16 e6/e7 vaccine ibrx-042, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Participants With HPV-Associated Tumors.
Primary endpoint: Determine the maximum tolerated dose of IBRX-042
Interventionalopen12 targetStarted 2024-06Completion 2033-082 sites · United StatesImmunityBio, Inc.